Organogenesis (NASDAQ:ORGO - Get Free Report) had its price objective raised by investment analysts at Cantor Fitzgerald from $7.00 to $9.00 in a research report issued on Friday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Cantor Fitzgerald's target price indicates a potential upside of 115.05% from the stock's current price.
Separately, BTIG Research reiterated a "buy" rating on shares of Organogenesis in a report on Tuesday, July 15th.
Get Our Latest Stock Analysis on ORGO
Organogenesis Stock Down 7.4%
ORGO traded down $0.34 during midday trading on Friday, hitting $4.19. The company had a trading volume of 491,306 shares, compared to its average volume of 1,480,036. The stock's 50 day moving average price is $3.94 and its 200 day moving average price is $4.05. Organogenesis has a 52 week low of $2.28 and a 52 week high of $6.71. The company has a market capitalization of $530.87 million, a price-to-earnings ratio of -24.62 and a beta of 1.76.
Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.17). Organogenesis had a negative net margin of 3.46% and a negative return on equity of 4.00%. The firm had revenue of $86.69 million during the quarter, compared to the consensus estimate of $90.77 million. Research analysts predict that Organogenesis will post -0.07 EPS for the current year.
Insider Buying and Selling at Organogenesis
In related news, insider Lori Freedman purchased 9,022 shares of the business's stock in a transaction on Friday, June 6th. The stock was acquired at an average price of $2.99 per share, for a total transaction of $26,975.78. Following the purchase, the insider owned 846,459 shares of the company's stock, valued at approximately $2,530,912.41. This trade represents a 1.08% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have bought 252,264 shares of company stock valued at $725,732. Corporate insiders own 33.00% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. grew its stake in shares of Organogenesis by 748.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,857,904 shares of the company's stock worth $10,460,000 after acquiring an additional 2,520,941 shares in the last quarter. Driehaus Capital Management LLC purchased a new position in Organogenesis during the first quarter worth about $7,756,000. Invesco Ltd. grew its position in Organogenesis by 779.7% in the 1st quarter. Invesco Ltd. now owns 1,069,252 shares of the company's stock worth $4,619,000 after purchasing an additional 947,705 shares in the last quarter. Vanguard Group Inc. grew its position in Organogenesis by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company's stock worth $19,144,000 after purchasing an additional 841,618 shares in the last quarter. Finally, Soleus Capital Management L.P. increased its stake in Organogenesis by 5.4% in the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company's stock valued at $39,952,000 after buying an additional 645,000 shares during the last quarter. Institutional investors own 49.57% of the company's stock.
About Organogenesis
(
Get Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Organogenesis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.
While Organogenesis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
